Learn more

In this section, you will learn more about Gattefossé Pharmaceuticals expertise, through news, hot topics and publications at the cutting edge of science, you can browse through a library of on-demands webinars, and download our latest brochures.

Hot Topics

Women's medicines

  • Pharmaceuticals

Every woman faces a gynecological disorder at some point in her life, during puberty, maternity, menopause or post menopause. These age periods structure the women’s health market with treatments for menopause related disorders, postmenopausal osteoporosis, infertility, endometriosis, gynecological cancer and birth control.

Pediatric medicines

  • Pharmaceuticals

Pediatric patients have specific needs we have to take into account when developing formulations:
- need for dose flexibility to adapt to the body weight
- difficulty to swallow pills
- very sensitive to bitterness
- delicate skin

Focus on some solutions adapted to these specific challenges.

Smiling pediatric patient at the doctor's office

Formulating cannabinoids with lipid excipients

  • Cannabinoids

Cannabinoids are challenging drugs to formulate

cannabis plant in front of a lab technician
View more


Introduction to oral bioavailability enhancement using lipid excipients.

  • Lipid-based formulations

Part 2: Step by step development of successful lipid-based formulations


Introduction to oral bioavailability enhancement using lipid excipients.

  • Lipid-based formulations

Part I: Lipid-based formulations to address oral bioavailability issues


Latest Publications

Self-emulsifying drug delivery systems (SEDDS): In vivo-proof of concept for oral delivery of insulin glargine

  • Scientific publication

May 2023

In this study, lipophilicity of insulin glargine (IG) was successfully increased via hydrophobic ion pairing (HIP) with sodium octadecyl sulfate to enable incorporation into self-emulsifying drug delivery systems (SEDDS). The SEDDS formulations F1 and F2 were administered to rats via oral gavage and resulted in a bioavailability of 0.55% and 0.44%, corresponding to a 7.7-fold and 6.2-fold increased bioavailability, respectively. Thus, incorporation of complexed insulin glargine into SEDDS formulations provides a promising approach to facilitate its oral absorption.

View more

All brochures

Gelucire 44/14

  • Brochure

Learn how to use this self-emulsifying excipient to increase oral drug bioavailability

  • Oral
Download (.pdf - 2.14 MB)

Labrasol ALF

  • Brochure

A nonionic water-dispersible surfactant for lipid-based formulations to solubilize and increase oral bioavailability of poorly water-soluble APIs. Self-emulsifies in aqueous media forming a fine dispersion, i.e., microemulsion (SMEDDS).

  • Oral
Download (.pdf - 5.35 MB)
View more